Biomarkers predict time to ovarian cancer recurrence

August 15, 2013

Ovarian cancer often remains undetected until it is at an advanced stage. Despite positive responses to initial treatment, many patients are at risk of tumor recurrence. A multitude of genetic markers have been implicated in ovarian cancer prognosis. However, the genetic testing required is not practical or affordable in a clinical setting.

In this issue of the Journal of Clinical Investigation, Roel Verchaak and colleagues at the MD Anderson Cancer Center identify protein biomarkers that are predictive for time of ovarian and develop a PRotein-driven index of OVARian cancer (PROVAR).

Using PROVAR, the authors were able to discriminate between patients with high and low risk of cancer recurrence, as well as short-term and long-term survival prognosis. In combination with genetic diagnosis, analysis of may be useful in predicting outcome and determining a treatment plan for ovarian cancer patients.

Explore further: Team finds markers related to ovarian cancer survival and recurrence

More information: Predicting Time to Ovarian Carcinoma Recurrence Using Protein Markers, J Clin Invest. DOI: 10.1172/JCI68509

Related Stories

Key find for early bladder cancer treatment

May 23, 2013

Aggressive forms of bladder cancer involve the protein PODXL – a discovery that could hold the key to improved treatment, according to researchers at Lund University, Uppsala University and KTH in Sweden.

Laparoscopic approach in early-stage ovarian cancer promising

August 13, 2013

(HealthDay)—Operative outcomes of laparoscopic approach in patients with early-stage ovarian cancer may be comparable with those of laparotomy, according to a meta-analysis published in the July issue of the American Journal ...

Recommended for you

Double whammy for triple negative breast cancer

December 5, 2016

A promising new combination therapy for a particularly aggressive form of breast cancer has been identified by Weizmann Institute scientists, as was recently reported in Cancer Research. The potential dual-acting therapeutic ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.